Objective To define the clinical features of myositis patients with anti-PM/Scl-75 and/or anti-PM/Scl-100 autoantibodies at disease onset and during the course of disease and compare them to patients with other forms of myositis.
In the present study, we performed a longitudinal cohort study of anti-PM/Scl-positive patients and analyzed their demographic, clinical, and laboratory features in comparison to patients with DM, AS, and IMNM. Furthermore, we investigated phenotypic differences between patients positive only for either anti-PM/Scl-75 or anti-PM/Scl-100 autoantibodies. 17, 18 were used as comparator groups; patients were classified as having AS if they had autoantibodies against Jo-1, PL-7, or PL-12, were included in the DM group if they had autoantibodies recognizing Mi2, NXP2, TIF1g, or MDA5, and were considered to have IMNM if they tested positive for anti-SRP or anti-HMGCR autoantibodies. Other factors, including the degree or pattern of muscle weakness, muscle biopsy findings, or extramuscular features (i.e., DM rash or AS-associated manifestations), were not used for categorization of the controls into AS, DM, or IMNM groups.
Methods

Study population and autoantibody testing
Strength was evaluated by the examining physician using the Medical Research Council scale. This scale was transformed to the Kendall 0-10 scale for analysis purposes as previously described. 19 Serial strength measurements for each patient were made by the same physician. For the purposes of analyses, right-and left-side measurements for arm abduction and hip flexion strength were combined and the average was used for calculations (possible range 0-10). Skin manifestations specific for DM (i.e., heliotrope rash or Gottron sign) and sclerodactyly (with or without skin thickening proximal to fingers with no other scleroderma-like disorder explaining the findings), symptoms of esophageal involvement, and ASassociated clinical features (e.g., mechanic's hands, Raynaud phenomenon, arthritis, fever) were documented both retrospectively at the onset of the disease and prospectively at each visit. ILD was defined through a multidisciplinary approach as recommended by the American Thoracic Society. 20 Pulmonary function testing included spirometry, lung volumes measured by helium dilution, and diffusing capacity by singlebreath carbon monoxide based on American Thoracic Society criteria. 21 Pulmonary hypertension was defined as definite if the patient had a mean pulmonary arterial pressure of ≥25 mm Hg at rest by right heart catheterization or as probable if an echocardiogram showed a right systolic ventricular pressure >40 mm Hg. 22 Muscle enzyme levels and pulmonary function tests were included for analysis if obtained within a period of 6 weeks before or after strength testing (except for peak, minimum, and mean values, of which all available data were included).
All available muscle biopsies from anti-PM/Scl-positive patients were evaluated for the presence of perivascular inflammation, perifascicular atrophy, primary inflammation (focal invasion of nonnecrotic muscle fibers by inflammatory cells), and necrotizing features (muscle fiber necrosis without primary inflammation or perifascicular atrophy).
Glossary AS = antisynthetase syndrome; CK = creatine kinase; DLCO = diffusing capacity of the lungs for carbon monoxide; DM = dermatomyositis; FVC = forced vital capacity; ILD = interstitial lung disease; IMNM = immune-mediated necrotizing myopathy; SSc = systemic sclerosis.
Thigh MRI was performed as explained elsewhere. 23 In short, we evaluated 15 muscles bilaterally in each patient, recording the presence of muscle edema, fascial edema, atrophy, or fatty replacement. The percentage of patients showing each one of the features in one or more muscles was used to compare anti-PM/Scl-positive patients to the remainder of the groups.
Standard protocol approvals and patient consents This study was approved by the Johns Hopkins institutional review board. Written informed consent was obtained from each participant.
Statistical analysis
Dichotomous variables were expressed as percentages and absolute frequencies, and continuous features were reported as means and SDs. Pairwise comparisons for categorical variables between groups were made using χ 2 test or Fisher exact test, as appropriate. Student t test was used to compare continuous variables among groups, and paired t test was used to compare the level of weakness of different muscle groups. Creatine kinase (CK), a highly positively skewed variable, was expressed as median, first, and third quartile for descriptive purposes and was transformed through a base-10 logarithm for regression analysis.
To account for differing numbers of visits per patient, the evolution of the pulmonary function tests, CK levels, and muscle strength were studied using multilevel linear regression models with random slopes and random intercepts. The mean of hip flexor and arm abductor strength (range 0-10) was used as the strength outcome for regression analysis.
Locally weighted regression was applied to graphically analyze the evolution of the strength, CK levels, and pulmonary function tests. Kaplan-Meier curves were used to study the evolution of each of the clinical features over time.
The influence of nonmodifiable risk factors (sex, race, duration of disease, and age at onset of the first symptom), the corticosteroid dose, and the administration of IV immunoglobulins, rituximab, methotrexate, azathioprine, and mycophenolate were used as adjusting covariates. Other treatments administered to less than 10% of the cohort were not included in the analysis.
As previously described, indirect standardization was used to compare the mortality and cancer risk that we observed in our sample with the number of cases that one would expect in the general population with the same age and sex distribution. 18 All statistical analyses were performed using Stata/MP 14.1. A 2-sided p value ≤0.05 was considered statistically significant with no adjustment for multiple comparisons.
Data availability
No unpublished data related to this study are publicly available.
Results
Patients
Of the 2,175 patients enrolled in the Myositis Center Longitudinal Cohort Study, which includes patients with both immune and nonimmune disorders, 949 patients had known or suspected myositis and were tested for myositis autoantibodies. Among these, 41 (4%) were positive for anti-PM/Scl autoantibodies, 26 (63%) were positive for both anti-PM/ Scl-75 and anti-PM/Scl-100, 8 (20%) were positive only for anti-PM/Scl-100, and 7 (17%) were positive only for anti-PM/Scl-75. The control groups, which were defined based on the presence of myositis-specific autoantibodies, were also identified from among Myositis Center patients with known or suspected myositis and included 178 patients with DM, 132 with AS, and 135 with IMNM. The general features of anti-PM/Scl and the control groups are detailed in table 1. Among the anti-PM/Scl-positive group, 30% met the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for SSc.
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No anti-PM/Scl-positive patient was also positive for another myositis-specific autoantibody. Among anti-PM/Scl-positive patients, the myositis-associated autoantibodies anti-Ro52 and anti-NT5C1a were found in 32% and 5%, respectively. No anti-PM/Scl patient died during the period of this study or developed cancer within 3 years of the onset of the autoimmune disease. Thus, compared with the normal population of the same age and sex, there was no increase in mortality rate (95% confidence interval 0-2.95) or cancer rate (95% confidence interval 0-3.4).
Muscle involvement
Patients with anti-PM/Scl have deltoid weakness greater than hip flexor weakness and muscle biopsies revealing intense perivascular inflammation At disease onset, weakness was present in a minority (37%) of anti-PM/Scl-positive patients but in a majority of patients with AS (55%, p < 0.05) and IMNM (81%, p < 0.001) (tables e-1 and e-2, links.lww.com/WNL/A506). However, during the follow-up period, most anti-PM/Scl, DM, AS, and IMNM patients developed weakness (93%, 85%, 90%, and 96%, respectively) with no differences between groups (table 2) . Similar to patients with DM and AS, patients with anti-PM/ Scl had modest proximal muscle weakness with mean hip flexor and mean arm abduction strength of 9.2 and 8.6 strength units, respectively. Patients in the anti-PM/Scl group had substantially stronger hip flexors than those in the IMNM group (6.7, p < 0.001). However, the mean arm abduction strength of the anti-PM/Scl patients was remarkably similar to those with IMNM (8.6 vs 8.5).
Of note, in patients with anti-PM/Scl, arm abductor strength was decreased compared to hip flexors (8.6 vs 9.2, p = 0.03). The opposite pattern of arm abduction vs hip flexor strength was observed in patients with AS (9.3 vs 9.0, p < 0.001), DM (9.1 vs 8.8, p = 0.001), and IMNM (8.5 vs 6.7, p < 0.001) (table 3). In anti-PM/Scl-positive patients, the degree of arm abductor weakness was associated with age at onset; specifically, younger patients had decreased strength in this muscle group compared with older participants (p < 0.001). Of note, 9 (23%) anti-PM/Scl-positive patients also had distal weakness. Among these, 7 (88%) did not have significant sclerodactyly or arthritis to suggest that the distal weakness was independent of the muscle disease.
Multilevel regression analysis confirmed that anti-PM/Scl patients were stronger than patients with IMNM (1.4 strength points difference, p < 0.001) but were not weaker than patients with AS and DM, independent of the time from onset, age, sex, race, or treatments at any given time during follow-up. Anti-PM/Scl patients who were positive for antiRo52 showed more severe muscle involvement in the univariate analysis (mean hip flexor strength 8.3 vs 9.6, p = 0.01; mean arm abductor strength 7.5 vs 9.1, p = 0.03), but this result was not confirmed in the multilevel study.
Patients with significant weakness at the first visit tended to regain full strength within the first year of treatment (figure e-1, links.lww.com/WNL/A505) using a combination therapy of corticosteroids plus mycophenolate, methotrexate, or azathioprine. Significant flares of weakness (defined either as increasing CK levels or worsening weakness) after treatment introduction were exceptional in our cohort. Perivascular inflammation, found in 17 of 21 (81%) available muscle biopsies, was the most common histopathologic feature in patients with anti-PM/Scl antibodies; these perivascular collections were often quite extensive (figure 1). Perifascicular atrophy was noted in just 24% of anti-PM/Scl biopsies; this was decreased compared to biopsies from DM (56%, p = 0.02) and AS (52%, p = 0.05). Predominant perifascicular necrosis was not observed. Necrosis without primary inflammation (i.e., lymphocytic invasion of healthy myofibers) or perifascicular atrophy was less common in the anti-PM/Scl group than in IMNM Cancer associated myositis, % (n) 0 (0) 8 (15) 3 (4) 5 (7) Death during follow-up, % (n) 0 (0) 4 (7) 10 (13) (24% vs 80%, p < 0.001) but had a similar frequency in DM (13%) and AS (22%). Primary inflammation was more common in anti-PM/Scl (33%) patients than in DM (9%, p = 0.03) but occurred at a similar frequency in IMNM (16%) and AS (30%).
Immunostaining for MHC-I was performed in 5 anti-PM/Sclpositive cases; 3 cases had diffuse MHC-I upregulation and a fourth case had predominant perifascicular MHC-I staining. Only 3 cases were stained for membrane attack complex and this was negative in each case. Five cases were stained for alkaline phosphatase and none of these had increased staining of the perimysium as reported in some types of myositis (e. g., AS).
Of note, thigh MRI revealed muscle edema less frequently in anti-PM/Scl-positive patients (39%) compared to all the other myositis control groups (71% in DM, 76% in AS, and 90% in IMNM, all p < 0.008). In anti-PM/Scl-positive patients, the prevalence of atrophy (22%) and fatty replacement (50%) was lower than in IMNM (each p < 0.001) (table 3) .
EMG revealed an irritable myopathy in 40% of anti-PM/Scl patients, which was observed in a similar proportion of patients with DM (45%) and AS (39%) and in a higher proportion of patients with IMNM (77%, p < 0.001) (table 3) .
Interstitial lung disease Anti-PM/Scl patients have mild ILD
At disease onset, ILD was present in just 10% of anti-PM/Scl patients, which was similar to the prevalence of ILD in those with DM (6%) and increased compared to those with IMNM (1%, p < 0.05). Compared to those with anti-PM/Scl, early ILD was more common in those with AS (52%, p < 0.001). Despite the infrequency of ILD at onset, during the course of disease, 61% of anti-PM/Scl patients eventually developed this lung manifestation. Although patients with AS were even more likely to develop ILD over time (80%, p < 0.05), patients with DM were less likely to develop ILD (13%, p < 0.001) than those with anti-PM/Scl autoantibodies (table 2) .
When present, lung involvement in anti-PM/Scl patients appeared to be milder than in patients with AS (table 3) . Overall, percentage-predicted forced vital capacity (%FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) in the anti-PM/Scl patients tended to be stable over time (data not shown). Nevertheless, during the first 6 months after the first visit, percentage-predicted FVC tended to increase with no change in the DLCO, suggesting that the cause of functional lung improvement during this period was due to recovery of muscle function (data not shown). Multilevel regression analysis confirmed that, at any given point during follow-up and independently of the age at onset, race, sex, or treatment regimen, anti-PM/Scl patients had higher % FVC than patients with AS (13% difference, p = 0.003) and were not different compared to patients with DM or IMNM (both p > 0.05).
Pulmonary hypertension was virtually unheard of in patients with anti-PM/Scl (0%), DM (0%), AS (1%), or IMNM (0%) at disease onset (table 2) . However, over time, 12% of anti-PM/Scl patients developed definite or probable pulmonary hypertension. In contrast, only 3% (p < 0.05) of patients with DM and 1% (p < 0.05) of patients with IMNM were ever diagnosed with pulmonary hypertension. When present, pulmonary hypertension in anti-PM/Scl patients was mild, usually secondary to ILD, and did not require any specific management.
Extramuscular clinical features Anti-PM/Scl patients have highly prevalent extramuscular clinical features
Compared to the other groups, the onset of disease in anti-PM/Scl patients was more frequently associated with sclerodactyly (table e-1, links.lww.com/WNL/A506). Similar to patients with early AS, patients with early anti-PM/Scl were more likely to have Raynaud syndrome and mechanic's hands than those with DM or IMNM (all p < 0.001). During the course of the disease, many skin features were more prevalent in anti-PM/Scl patients compared to the other groups (table  2) . Most developed heliotrope or Gottron rashes (85%), mechanic's hands (80%), sclerodactyly (66%), Raynaud phenomenon (78%), and/or telangiectasias (66%). Other cutaneous findings such as calcinosis (39%), subcutaneous edema (46%), and/or puffy hands (39%) were more common and appeared at a faster rate in anti-PM/Scl-positive patients than in patients from the other groups (table 2 ; figure e-2, links.lww.com/WNL/A505). Gastroesophageal reflux eventually occurred in 61% of anti-PM-Scl patients, which was increased compared to the other groups. Arthritis documented on clinic examination (46%) and sicca syndrome (59%) were more common in anti-PM/Scl patients than in patients with DM or IMNM (table 2, figure e-2). It is of interest that mechanic's hands were present in even more anti-PM/Scl-positive patients than in patients with AS (80% vs 58%, p < 0.05). Of note, clinical features associated with severe SSc, such as the presence of renal crisis (3%) or hand ulceration (5%), were uncommon in anti-PM/Scl patients. We did not find other differences in clinical features or disease activity between anti-PM/Scl patients with heliotrope rash, Gottron sign, or perifascicular atrophy and those without these characteristics.
Both at onset and during the course of the disease, patients positive for both anti-PM/Scl-75 and anti-PM/Scl-100 showed very similar phenotypes and severity of disease compared to those positive for just one of these autoantibodies (tables e-3 to e-5).
Discussion
In this study, we have defined the unique clinical phenotype of patients with anti-PM/Scl autoantibodies. First, patients with anti-PM/Scl autoantibodies have a distinctive pattern of muscle weakness in which arm abductors are weaker than hip flexors. In contrast, hip flexors are weaker than arm abductors in those with DM, AS, or IMNM. Of note, clinicians at the Johns Hopkins Myositis Center have anecdotally noted marked deltoid atrophy (in the absence of diffuse scleroderma causing skin tightening) in several anti-PM/Scl patients. Although data regarding this clinical feature were not systematically collected in all patients, we suspect deltoid atrophy Neurology.org/N may be a distinguishing feature of patients with anti-PM/Scl myositis and that this explains the unique pattern of weakness in these patients. Future prospective studies using ultrasound or imaging to quantify deltoid atrophy will be important to confirm this observation.
Second, compared to the other groups, anti-PM/Scl-positive patients are more likely to have extramuscular manifestations including mechanic's hands, Raynaud syndrome, sclerodactyly, telangiectasias, esophageal reflux disease, subcutaneous edema, puffy hands, and calcinosis. Of note, anti-PM/Scl-positive patients were even more likely than patients with AS to have 2 of the classic features of AS: mechanic's hands and Raynaud syndrome. Similarly, although calcinosis is known to be a concern in patients with DM, this feature occurred even more frequently in those with anti-PM/Scl autoantibodies. These observations highlight the utility of testing for myositis autoantibodies, which correlate with unique clinical phenotypes.
Additional insight into the anti-PM/Scl phenotype can be gleaned by comparing this group to each of the other groups individually. Compared to the DM group, anti-PM/Scl-positive patients were just as likely to initially present with muscle, lung, and joint involvement but less likely to have Gottron sign or a heliotrope rash. However, during the course of disease, anti-PM/Scl-positive patients were more likely to develop lung and joint involvement than patients with DM. It is of interest that while 85% to 96% of both anti-PM/Scl-positive and DM patients eventually developed muscle weakness and the classic skin manifestations of DM, muscle biopsies from only onequarter of the former patients had perifascicular atrophy (the pathognomonic muscle biopsy feature of DM) compared with more than half of the latter. Anti-PM/Scl patients were also more likely to have primary inflammation than patients with DM. These histopathologic findings suggest that the mechanisms underlying myositis in anti-PM/Scl patients may be different than those in patients with DM.
Anti-PM/Scl-positive and AS patients also presented differently. For example, patients with AS were more likely to have muscle weakness, ILD, and joint involvement and less likely to have Gottron sign or heliotrope rash. However, as the disease progressed, anti-PM/Scl-positive and AS patients experienced similar rates of muscle weakness and joint involvement. During disease evolution, patients with AS continued to have higher rates of ILD and more severe ILD. The observation that patients with AS had lower FVCs despite a tendency to be stronger than anti-PM/Scl patients suggests that the difference in FVC was not attributable to a difference in diaphragmatic strength. Muscle biopsies were similar when comparing anti-PM/Scl to AS patients.
Patients with IMNM were phenotypically most distinct from those with anti-PM/Scl autoantibodies. Patients with IMNM were more likely to have weakness at disease onset and during the course of follow-up. Patients with IMNM also had higher peak CK levels and more severe weakness of the hip flexors, knee flexors, and knee extensors than anti-PM/Scl patients. Of note, patients with IMNM were not weaker than anti-PM/Scl patients in the upper extremities; this reflects the distinct pattern of muscle weakness already described in the latter group. Finally, muscle biopsies from anti-PM/Scl-positive patients were more likely to have primary inflammation and less likely to have a necrotizing muscle biopsy compared to patients with IMNM.
It has been reported 25 that antibodies against PM/Scl-75 and PM/Scl-100 identify different subsets of patients with SSc. However, in the current study, we detected no clinical differences between patients with only anti-PM/Scl-75 or only anti-PM/Scl-100 autoantibodies.
In accordance with other studies describing muscle biopsies from patients with anti-PM/Scl autoantibodies, 12, 26 we found that the muscle biopsy features in these patients included a predominance of perivascular inflammation but scarce perifascicular atrophy compared to patients with DM or AS.
In this longitudinal cohort study, we show that in patients positive for anti-PM/Scl autoantibodies, muscle involvement is responsive to immunosuppressant treatment and patients tend to recover well during the first year of treatment. In addition, ILD seems to be stable over time in these patients, and recovery during the first months of follow-up appears to be associated with an increase in the strength of respiratory muscles. The fact that lung functional impairment is stable during follow-up suggests that the inflammatory phase of the ILD occurs soon after the onset of the syndrome, with subsequent residual irreversible damage.
In this study, we have shown that patients with anti-PM/Scl autoantibodies have a distinct clinical phenotype characterized by extensive extramuscular manifestations and a unique pattern of weakness in which arm abductors are weaker than hip flexors. We also found that anti-PM/Scl-positive patients have little in common with IMNM patients but do share certain features with AS patients (e.g., frequent ILD, arthritis, and mechanic's hands) and DM patients (frequent heliotrope rash and Gottron papules). Since patients with anti-PM/Scl autoantibodies have a unique phenotype, we propose that future classification schemes should recognize "the anti-PM/Scl syndrome" as a distinct subtype of myositis. Future studies will be required to determine whether anti-PM/Scl autoantibodies are pathogenic or epiphenomena of some other process.
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